Jennison Associates LLC Boosts Stake in uniQure N.V. $QURE

Key Points

• Jennison Associates LLC increased its position in uniQure by 37.2% in Q4 to 1,371,190 shares, roughly 2.20% of the company valued at about $32.8 million.
• uniQure said it had a successful pre-submission meeting with the U.K. MHRA for gene therapy AMT‑130 and expects to file a U.K. Marketing Authorization Application in Q3 2026, triggering positive market reaction and analyst upgrades.
• Insiders have been net sellers recently—CFO Christian Klemt and Jeannette Potts sold shares on March 4, and insiders sold a total of 49,396 shares in the past 90 days, leaving insiders with about 4.79% ownership.

Jennison Associates LLC raised its position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) by 37.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,371,190 shares of the biotechnology company's stock after acquiring an additional 371,706 shares during the period. Jennison Associates LLC owned approximately 2.20% of uniQure worth $32,813,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp grew its position in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 509 shares during the period. China Universal Asset Management Co. Ltd. grew its position in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company's stock valued at $243,000 after acquiring an additional 533 shares during the period. Arizona State Retirement System grew its position in uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company's stock valued at $267,000 after acquiring an additional 627 shares during the period. FNY Investment Advisers LLC grew its position in uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 718 shares during the period. Finally, CIBC Private Wealth Group LLC purchased a new stake in uniQure during the third quarter valued at about $50,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

Insider Transactions at uniQure

In other news, CFO Christian Klemt sold 12,000 shares of uniQure stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the sale, the chief financial officer directly owned 226,581 shares of the company's stock, valued at approximately $2,052,823.86. The trade was a 5.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jeannette Potts sold 3,412 shares of uniQure stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the sale, the insider directly owned 138,483 shares in the company, valued at approximately $1,254,655.98. The trade was a 2.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 49,396 shares of company stock valued at $722,734. 4.79% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on QURE shares. Leerink Partners reissued an "outperform" rating and set a $35.00 price target on shares of uniQure in a research report on Monday, March 2nd. The Goldman Sachs Group boosted their price objective on uniQure from $9.00 to $10.00 and gave the stock a "neutral" rating in a research note on Monday, April 20th. Royal Bank Of Canada upgraded uniQure from a "sector perform" rating to an "outperform" rating and boosted their price objective for the stock from $11.00 to $35.00 in a research note on Monday, March 9th. Wolfe Research started coverage on uniQure in a research note on Monday, February 23rd. They set a "peer perform" rating on the stock. Finally, Stifel Nicolaus set a $14.00 price objective on uniQure in a research note on Monday, March 2nd. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.33.

uniQure Trading Down 4.1%

Shares of QURE opened at $19.13 on Friday. The stock's 50-day moving average is $16.75 and its two-hundred day moving average is $26.01. The stock has a market cap of $1.21 billion, a PE ratio of -5.54 and a beta of 0.75. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $0.37. The company had revenue of $5.57 million for the quarter, compared to analysts' expectations of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. Equities analysts forecast that uniQure N.V. will post -3.6 earnings per share for the current fiscal year.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported a successful pre-submission meeting with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for AMT‑130 and said it expects to submit a U.K. Marketing Authorization Application in Q3 2026 — a clear pathway to pursue approval outside the U.S. and a major near-term regulatory milestone. uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130
• Positive Sentiment: Market coverage and outlets reported an immediate positive market reaction to the U.K. update (coverage noted intraday gains), reflecting investor optimism that a U.K. approval route could salvage commercial prospects after prior U.S. regulatory friction. QURE stock just shot up 8% - MSN
• Positive Sentiment: Analyst support: Chardan Capital raised its price target from $31 to $37 and reiterated a "buy" rating, increasing upside expectations and likely supporting bullish sentiment. Benzinga Coverage of Chardan PT Raise
• Neutral Sentiment: Corporate calendar: uniQure is expected to announce quarterly earnings on Tuesday — this event could amplify short-term volatility as investors reassess guidance, cash burn and program timelines. Earnings Date Notice
• Negative Sentiment: Regulatory risk remains material: coverage highlights prior disagreements with the U.S. FDA over AMT‑130; while the U.K. route is promising, successful MHRA interactions don’t eliminate the possibility of later setbacks or additional data requirements. Biospace on FDA Quarrel and UK Strategy
• Negative Sentiment: Fundamental risks: uniQure remains loss-making with limited current revenue, making its valuation highly sensitive to regulatory and commercial outcomes for AMT‑130 and other pipeline assets. (Refer to recent financials for full detail.)

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.